Advanced Solid Tumors Cancer: Clinical Trials

24 trials for Advanced Solid Tumors Cancer, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 recruiting, 7 completed, 4 active not recruiting, 4 not yet recruiting. 20 Phase 1, 6 Phase 2, 1 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 120Completed 6, Recruiting 6, Active not recruiting 4, Not yet recruiting 3, Terminated 1
Phase 26Recruiting 4, Not yet recruiting 2
Not applicable1Not yet recruiting 1

Follow Advanced Solid Tumors Cancer: new trials by email Literature Review of Advanced Solid Tumors Cancer trials Research Report on Advanced Solid Tumors Cancer

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.
Signatera Genome ultra-sensitive ctDNA blood test - NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer)
Not applicableNot yet recruitingNatera, Inc.9202027-01-012026-10-27
Autologous Tumor Infiltrating Lymphocyte (TIL) GT201 Infusion.
GT201, IL-2 and PD-1 - Advanced Solid Tumors Cancer
Phase 1 / Phase 2Not yet recruitingGritbio Medicine, Inc.632026-11-012026-08-14
Trial to Study the Safety, Pharmacokinetics and Preliminary Antitumour Activity of ODM-216 in Patients With Cancer
ODM-216 - Advanced Solid Tumors Cancer
Phase 1 / Phase 2RecruitingOrion Corporation, Orion Pharma1952026-09-032026-09-24
A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation
GFH276, Cetuximab, Nab paclitaxel - Advanced Solid Tumors Cancer, Pancreatic Ductal Adenocarcinoma
Phase 1 / Phase 2RecruitingGenfleet Therapeutics (Shanghai) Inc.2222026-09-012026-10-05
First-In-Human Study of KHN922 for Injection
KHN922 for injection - Advanced Solid Tumors Cancer
Phase 1 / Phase 2Not yet recruitingChengdu Kanghong Biotech Co., Ltd.2762026-04-012026-04-09
A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation
GFH375 - Advanced Solid Tumors Cancer, PDAC
Phase 1 / Phase 2RecruitingGenfleet Therapeutics (Shanghai) Inc.1262025-10-212025-12-02
PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer
PQ203 - Triple Negative Breast Cancer (TNBC), Advanced Solid Tumors Cancer
Phase 1RecruitingProteinQure Inc.802025-09-162026-02-23
A Study of KC1086 in Patients With Advanced Solid Tumors
KC1086 - Advanced Solid Tumors Cancer
Phase 1Not yet recruitingBeijing Konruns Pharmaceutical Co., Ltd.662025-08-012025-08-12
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
Biopsy - Cancer, Immunotherapy
RecruitingElephas20002025-04-142026-06-29
A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.
NDI-219216 - Advanced Solid Tumors Cancer, MSI-H Cancer
Phase 1 / Phase 2RecruitingNimbus Wadjet, Inc.1342025-03-312026-05-06
ORB-021 In Patients With Advanced Solid Tumors
ORB-021 - Advanced Solid Tumors Cancer
Phase 1RecruitingOrionis Biosciences Inc362024-11-212026-08-26
Clinical PhenoAge and Mortality After Unplanned Hospital Admission in Metastatic Cancer
Retrospective Assessment of Clinical PhenoAge and Prognostic Scores - Advanced Solid Tumors Cancer, Hospitalizations
CompletedAnkara Etlik City Hospital43212022-11-052026-11-12
ET-SPACE Whole-Body Infrared Hyperthermia in Patients With Advanced Solid Tumors
Advanced Solid Tumors, Advanced Solid Tumors Cancer
RecruitingZhejiang Hospital5002022-01-012026-08-28
Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors
ABBV-637, Docetaxel, Osimertinib - Advanced Solid Tumors Cancer, Non Small Cell Lung Cancer (NSCLC)
Phase 1Active not recruitingAbbVie812021-02-232025-07-03
First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors
ABBV-CLS-579, PD-1 inhibitor, VEGFR TKI - Advanced Solid Tumors Cancer
Phase 1CompletedAbbVie1012020-06-032025-09-25
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
ABBV-368, Tilsotolimod, Nab-paclitaxel - Advanced Solid Tumors Cancer
Phase 1CompletedAbbVie302020-01-222023-02-27
Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors
Livmoniplimab, Budigalimab - Advanced Solid Tumors Cancer
Phase 1Active not recruitingAbbVie3642019-02-212025-05-25
A Study to Evaluate the Safety and Pharmacokinetics ABBV-399 in Japanese Participants With Solid Tumors
ABBV-399 - Advanced Solid Tumors Cancer
Phase 1CompletedAbbVie92017-11-062019-03-14
A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)
ABBV-321 - Advanced Solid Tumors Cancer
Phase 1CompletedAbbVie622017-10-102021-05-06
A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)
ABBV-176 - Advanced Solid Tumors Cancer
Phase 1TerminatedAbbVie192017-07-032018-11-29

Showing 20 of 24. Sign in to see all of them.

Narrower conditions

Neoplasms (14)  ·  Carcinoma, Non-Small-Cell Lung (7)  ·  Colorectal Neoplasms (5)  ·  Squamous Cell Carcinoma of Head and Neck (5)  ·  Melanoma (4)  ·  Triple Negative Breast Neoplasms (4)  ·  Carcinoma, Hepatocellular (3)  ·  Carcinoma, Renal Cell (2)  ·  Neoplasm Metastasis (2)  ·  Ovarian Neoplasms (2)  ·  Adrenocortical Carcinoma (1)  ·  Breast Neoplasms (1)  ·  Cancer Pain (1)  ·  Carcinoma, Merkel Cell (1)  ·  Carcinoma, Squamous Cell (1)

Broader conditions

Neoplasms by Site (13)  ·  Neoplasms by Histologic Type (9)  ·  Carcinoma (8)  ·  Neoplasms, Glandular and Epithelial (8)  ·  Bronchial Neoplasms (7)  ·  Carcinoma, Bronchogenic (7)  ·  Lung Diseases (7)  ·  Lung Neoplasms (7)  ·  Respiratory Tract Diseases (7)  ·  Respiratory Tract Neoplasms (7)  ·  Skin Diseases (7)  ·  Skin and Connective Tissue Diseases (7)  ·  Thoracic Neoplasms (7)  ·  Digestive System Diseases (6)  ·  Digestive System Neoplasms (6)

Interventions

budigalimab (4)  ·  Cetuximab (2)  ·  Gemcitabine (2)  ·  Nivolumab (2)  ·  Taxes (2)  ·  osimertinib (2)  ·  telisotuzumab vedotin (2)  ·  130-nm albumin-bound paclitaxel (1)  ·  ABBV-428 (1)  ·  Biopsy (1)  ·  Docetaxel (1)  ·  Erlotinib Hydrochloride (1)  ·  Fluorouracil (1)  ·  Immune Checkpoint Inhibitors (1)  ·  Injections (1)

Sponsors

AbbVie (11)  ·  Genfleet Therapeutics (Shanghai) Inc. (2)  ·  Ankara Etlik City Hospital (1)  ·  Beijing Konruns Pharmaceutical Co., Ltd. (1)  ·  Chengdu Kanghong Biotech Co., Ltd. (1)  ·  Elephas (1)  ·  Gritbio Medicine, Inc. (1)  ·  Natera, Inc. (1)  ·  Nimbus Wadjet, Inc. (1)  ·  Orion Corporation, Orion Pharma (1)  ·  Orionis Biosciences Inc (1)  ·  ProteinQure Inc. (1)  ·  Zhejiang Hospital (1)

Countries

United States (14)  ·  France (9)  ·  Spain (9)  ·  Australia (8)  ·  Japan (7)  ·  Taiwan (6)  ·  Israel (5)  ·  South Korea (5)  ·  Canada (4)  ·  China (4)  ·  Belgium (2)  ·  Germany (2)  ·  Italy (2)  ·  Netherlands (2)  ·  Puerto Rico (2)

Top investigators

Anita Scheuber, MD, PhD (1)  ·  Glenn Hanna, MD (1)  ·  Lin Shen, MD (1)  ·  Qing Zhou (1)  ·  Robert Petit, PhD (1)  ·  Xin Wang (1)  ·  Yan Zhang (1)

Results publications

PMID 30285518, PMID 32524319, PMID 33608377, PMID 33675179, PMID 34426443, PMID 36288547, PMID 36814898, PMID 39534099, PMID 39805351, PMID 41956545

NIH funding

2016 (4), 2014 (1), 2019 (1), 2023 (1)